By Lewis Krauskopf NEW YORK, April 7 (Reuters) – Clinical data on potential treatments for the new coronavirus could help sustain a market bounce that has buoyed stocks
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Gilead Sciences (GILD) has positioned itself at the front line in the global war against COVID-19. The biotech’s experimental drug remdesivir
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Zoom Video Communications (ZM) has been the saving grace for millions of people stuck at home, trying to figure out how
The new coronavirus outbreak and economic measures to contain it could have a significantly negative impact on retirement preparations for millions of Americans. Account balances have been depleted
For years, many Gold Bugs (investors who’ve been advocating buying Gold and Silver at low prices as a hedge against future global economic risks) were shunned as conspiracy
Veteran markets strategist James McDonald, CEO of Hercules Investments, is staying with a call that he has had throughout the coronavirus pandemic fueled bear market, now going on
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Executive Summary: Two weeks ago we predicted that the U.S. death toll from COVID-19 would reach 20,000 by April 15th. The
April 3 (Reuters) – The European Medicines Agency (EMA) on Friday recommended Gilead Sciences Inc’s investigational antiviral drug remdesivir should be used for treating COVID-19 in compassionate use
FILE PHOTO: Various N95 respiration masks at a laboratory of 3M, that has been contracted by the U.S. government to produce extra marks in response to the country’s
